Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.
El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...
Medicare Part D plans can only cover obesity ... Lilly and its main rival in the obesity-drug race, Denmark's Novo Nordisk (NVO) (DK:NOVO.B), are conducting trials to evaluate GLP-1 drugs as ...
Ozempic, Wegovy and other new drugs are selected for Medicare's price negotiations - The Biden administration says popular ...
President-elect Donald Trump says he “most likely” will give TikTok 90 more days to work out a deal that would allow the ...
Novo Nordisk A/S (NYSE:NVO), a multinational pharmaceutical company, saw its share prices on Friday retreat by 5.27 percent ...
Trump said he got Mexico to agree to stop migration through Mexico. Trump claims his influence caused the Israel-Hezbollah truce, that he got Canada to stop the U.S. opioid crisis and that he caused ...
In a wide-ranging interview, Xavier Becerra, President Biden’s health secretary, defended his tenure and hinted that he might ...
As Trump attempts to come to terms with the transition from campaign mode to serving in government, three areas of tension ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback